Abstract

Naïve CD4+ T cells coordinate the immune response by acquiring an effector phenotype in response to cytokines. However, the cytokine responses in memory T cells remain largely understudied. Here we use quantitative proteomics, bulk RNA-seq, and single-cell RNA-seq of over 40,000 human naïve and memory CD4+ T cells to show that responses to cytokines differ substantially between these cell types. Memory T cells are unable to differentiate into the Th2 phenotype, and acquire a Th17-like phenotype in response to iTreg polarization. Single-cell analyses show that T cells constitute a transcriptional continuum that progresses from naïve to central and effector memory T cells, forming an effectorness gradient accompanied by an increase in the expression of chemokines and cytokines. Finally, we show that T cell activation and cytokine responses are influenced by the effectorness gradient. Our results illustrate the heterogeneity of T cell responses, furthering our understanding of inflammation.

Cytokines critically control the differentiation and functions of activated naïve and memory T cells. Here the authors show, using multi-omics and single-cell analyses, that naïve and memory T cells exhibit distinct cytokine responses, in which an ‘effectorness gradient’ is depicted by a transcriptional continuum, which shapes the downstream genetic programs.

Details

Title
Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4+ T cells to cytokines
Author
Cano-Gamez, Eddie 1 ; Soskic Blagoje 1   VIAFID ORCID Logo  ; Roumeliotis, Theodoros I 2 ; So, Ernest 2 ; Smyth, Deborah J 3 ; Baldrighi Marta 3   VIAFID ORCID Logo  ; Willé, David 4 ; Nakic Nikolina 5 ; Esparza-Gordillo, Jorge 6 ; Larminie Christopher G C 6 ; Bronson, Paola G 7 ; Tough, David F 8 ; Rowan, Wendy C 9 ; Choudhary, Jyoti S 2   VIAFID ORCID Logo  ; Trynka Gosia 3   VIAFID ORCID Logo 

 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK; Wellcome Genome Campus, Open Targets, Cambridge, UK 
 The Institute of Cancer Research, Functional Proteomics, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623) 
 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.18886.3f); Wellcome Genome Campus, Open Targets, Cambridge, UK (GRID:grid.18886.3f) 
 GSK R&D, Biostatistics, Stevenage, UK (GRID:grid.18886.3f) 
 GSK R&D, Functional Genomics, Medicinal Science and Technology, Stevenage, UK (GRID:grid.18886.3f) 
 GSK R&D, Human Genetics, Stevenage, UK (GRID:grid.18886.3f) 
 R&D Translational Biology, Biogen, Human Target Validation Core, Cambridge, USA (GRID:grid.417832.b) (ISNI:0000 0004 0384 8146) 
 GSK R&D, Adaptive Immunity RU, Stevenage, UK (GRID:grid.417832.b) 
 GSK R&D, Novel Human Genetics, Stevenage, UK (GRID:grid.417832.b) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2389713148
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.